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SUMMARY – Th is case report presents a patient diagnosed with Tolosa-Hunt syndrome (THS) 
after an extensive neuro-diagnostic and neuroimaging evaluation. Diagnostic work-up included thor-
ough physical and neurological examination, complete laboratory serum assessments, neuroendocrine 
and immunohistochemistry analysis, cerebrospinal fl uid analysis, neurophysiology assessment, oph-
thalmologist examination and neuroimaging. Th e most important diagnostic tool in deriving the di-
agnosis of THS was neuroimaging evaluation that included baseline and follow-up cranial contrast 
enhanced magnetic resonance imaging (MRI). Baseline cranial contrast enhanced MRI detected a 
nonspecifi c infl ammatory granulomatous lesion in the right cavernous sinus extending basally towards 
the right trigeminal cave (Meckel‘s cave) and anteriorly towards the apex of the right orbit. Systemic 
intravenous high-dose corticosteroid therapy was administered for 3 consecutive days and then ta-
pered down to lower oral steroid doses. Following therapy, the patient experienced complete regres-
sion of symptoms. Follow-up cranial contrast enhanced MRI showed signifi cant regression of infl am-
matory lesion in the area of right cavernous sinus, thus verifying the effi  cacy of the treatment applied. 
Th is paper shows that an extensive diagnostic schedule for THS must be conducted prior to therapeu-
tic treatment, for the possibility of alternative diagnosis. Patients suspected of having THS require 
careful evaluation, appropriate treatment, and follow-up.
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Introduction
Tolosa-Hunt syndrome (THS) is a painful, usually 
unilateral ophthalmoparesis or ophthalmoplegia caused 
by nonspecifi c infl ammation (granulomatous or non-
granulomatous) of the cavernous sinus or superior or-
bital fi ssure. Constant or episodic severe retro-orbital 
or periorbital pain is the initial feature of THS that 
usually resolves spontaneously but tends to relapse and 
remit. Double vision (diplopia) related to ophthalmo-
paresis or disordered eye movement occurs when cra-
nial oculomotor (III), trochlear (IV), and abducens 
(VI) nerves are damaged by granulomatous infl amma-
tion. Evidence of incomplete third nerve palsy with or 
without pupillary sparing may be present. Ptosis may 
be observed due to oculomotor palsy1. Th e etiology of 
THS remains unknown, although it might be com-
monly related to trauma, neoplasm, aneurysm, and in-
fl ammation. It is known that THS responds well to 
systemic corticosteroid therapy, due to relapsing and 
remitting course. THS is rare during the fi rst 2 de-
cades of life and afterwards it appears to have an even 
distribution. According to the International Headache 
Society 2013 classifi cation, THS is described as uni-
lateral orbital pain associated with paresis of one or 
more of the third, fourth and/or fi fth cranial nerves 
caused by granulomatous infl ammation in the cavern-
ous sinus, superior orbital fi ssure or orbit. Diagnostic 
criteria for the diagnosis of 13.7 THS, defi ned by the 
3rd edition of the International Classifi cation of Head-
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ache Disorders (ICHD-3), include: A. Unilateral 
headache fulfi lling criterion C; B. Both of the follow-
ing: 1) granulomatous infl ammation of the cavernous 
sinus, superior orbital fi ssure or orbit, demonstrated by 
MRI or biopsy; 2) paresis of one or more of the ipsilat-
eral third, fourth and/or fi fth cranial nerves; C. Evi-
dence of causation demonstrated by both of the fol-
lowing: 1) headache has preceded paresis of the third, 
fourth and/or sixth nerves by ≤2 weeks, or developed 
with it; 2) headache is localized around the ipsilateral 
brow and eye; and D. Not better accounted for by an-
other ICHD-3 diagnosis2. Pupillary dysfunction is re-
lated to injury of sympathetic fi bers in the cavernous 
portion of internal carotid artery (ICA) or parasympa-
thetic fi bers that surround the oculomotor nerve. In-
fl ammatory involvement of the sympathetic nerves 
passing through the interior of the cavernous sinus 
may produce Horner syndrome with miosis. Th e com-
bination of unilateral oculomotor palsy and Horner 
syndrome increases the localization specifi city for the 
cavernous sinus. Some reported cases of 13.7 THS had 
additional involvement of the fi fth nerve (commonly 
the fi rst division) or optic, seventh or eighth nerves. 
Sympathetic innervation of the pupil is occasionally 
aff ected. Trigeminal nerve involvement of fi rst division 
(primarily V1) may cause paresthesia of the forehead. 
Evidence of trigeminal nerve involvement is suggested 
by loss of the ipsilateral corneal refl ex. Lid swelling is 
more likely to occur with orbital disease rather than 
infl ammation limited to the cavernous sinus. Also, 
mild proptosis and/or optic disc edema may be noted 
if the orbit is involved. Pathologic involvement beyond 
the cavernous sinus, superior orbital fi ssure, or apex of 
the orbit occurs rarely, and the disorder is part of a 
continuum with idiopathic orbital pseudotumor, with 
which it shares histopathology features. A single 
pathognomonic characteristic of THS does not exist, 
thus it is often considered as a diagnosis of exclusion. 
Many of the processes that are found within the dif-
ferential diagnosis of THS include tumors, vasculitis, 
Fig. 1. Clinical picture.
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basal meningitis, sarcoidosis, diabetes mellitus, and 
ophthalmoplegic migraine.
Case Report
A 54-year-old man was admitted to the Neurology 
Department, Sestre milosrdnice University Hospital 
Centre, due to severe frontal headache and right-sided 
periorbital pain, with the right eyelid ptosis and paresis 
of the right oculomotor cranial nerve. At admission, 
the patient was complaining of the right-sided supra-
orbital pain that expanded into the infraorbital area. 
During history taking, the patient reported that he 
had previously been hospitalized twice due to frontal 
headache, double vision and right-sided eyelid ptosis 
at neurology and ophthalmology departments, several 
months before. Medical history data revealed that in 
spite of the broad neurological and diagnostic exami-
nation, diagnosis has not been derived. After being 
discharged from the hospital, the patient experienced 
partial spontaneous regression of symptoms, without 
any treatment applied. At the current admission, the 
patient denied having nausea, fever, or recent head 
trauma. Alternative medical history was unremarkable 
Fig. 2. Magnetic resonance imaging of a 54-year-old man 
with severe periorbital pain in the right eye, complete 
right-sided oculomotor nerve palsy, and partial right-sided 
abducens nerve palsy. Coronal imaging with enhancement 
demonstrates nonspecifi c fullness involving the right 
cavernous sinus, consistent with Tolosa-Hunt syndrome.
Fig. 3. Imbibition of dural sheath along the right 
cavernous sinus (postcontrast T1 sections in transverse 
plane).
Fig. 4. Imbibition of dural sheath at the cone of the right 
orbit and right cavernous sinus. Imbibition of dural 
sheath at cranial part of the clivus (postcontrast T1 
sagittal sections).
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and tick bite was excluded. Th e patient declared as 
non-smoker but acknowledged the habit of occasional, 
socially acceptable drinking. Previously established 
therapy schedule included ibuprofen as needed, dulox-
etine daily, acetylsalicylic acid daily and ophthalmic 
formulation of tobramycin solution, twice a day. Th e 
patient denied possible allergy to medications. Physi-
cal and neurological examination performed at admis-
sion verifi ed upper right-sided eyelid ptosis, right-sid-
ed oculomotor cranial nerve palsy and partial right-
sided abducens nerve palsy without nystagmus (Fig. 
1). Emergency cranial multi-slice computed tomogra-
phy (MSCT) was reported normal, without any de-
tectable pathological morphological substrate. Labo-
ratory analysis included hematologic tests (complete 
blood count, serum chemistry, erythrocyte sedimenta-
tion rate, C-reactive protein), and the fi ndings were 
normal. During hospitalization, contrast enhanced 
magnetic resonance imaging (MRI) with diff erent se-
quences was performed. Post contrast T1 MRI weight-
ed images detected diff use enhancement in the area of 
the right cavernous sinus, extending basally towards 
the trigeminal cave and anteriorly towards the apex of 
the right orbit, with right-sided temporal-basal dural 
sheath imbibition and along the clivus. Hypointense 
Fig. 5. Signifi cant regression of post contrast signal 
intensity at the right cavernous sinus, along the right 
Meckel ’s cave, along the top of the pyramid of temporal 
bone and middle cranial fossa, and along the clivus.
signals were detected in the area of the right cavernous 
sinus and Meckel’s cave on short tau inversion recov-
ery (STIR) and T2 MRI weighted images (Figs. 2, 3 
and 4). In diff erential diagnosis, lesions were suggest-
ing a nonspecifi c infl ammatory reaction or granuloma-
tous infl ammation or possible lymphoid proliferative 
disease.
Cranial 3D time-of-fl ight (TOF) magnetic reso-
nance angiography (MRA) fi nding was normal with-
out any detectable aneurysm, vascular malformation or 
signifi cant stenosis in the cavernous or vertebral-basi-
lar area. Analysis of cerebrospinal fl uid (CSF) showed 
proper function of the blood-brain barrier and the ex-
istence of oligoclonal immunoglobulin G (IgG) bands, 
without intrathecal synthesis, suggesting a systemic 
immune response. Immunohistochemistry analysis of 
tumor markers (TPA, CEA, CA 19-9, CYFRA 21-1) 
and laboratory analysis of thyroid hormones showed 
normal values, but the analysis of circulating immune 
complexes in the serum showed elevated titers of im-
munoglobulin IgG and IgM. Th us, the patient was re-
ferred to hematologist who suggested further diagnos-
tic evaluation for possible vasculitis existence. Neuro-
physiology examination included blink refl ex and 
evoked potential testing: visual evoked potential 
(VEP), brainstem auditory evoked response (BAER) 
and somatosensory evoked potentials (SSEP). Find-
ings of the tests performed were all normal except for 
SSEP of the median nerve that showed bilateral so-
matosensory stimulus transfer dysfunction at the level 
of the thalamus and somatosensory cortex. Th e patient 
was referred to ophthalmology examination and visual 
fi eld analysis, which indicated narrowing of the right 
visual fi eld above that corresponding to the eyelid pto-
sis. Systemic intravenous corticosteroid therapy with 1 
000 mg methylprednisolone was administered for 3 
consecutive days, along with gastroprotective therapy 
and continuous monitoring of steroid-related adverse 
eff ects. Systemic intravenous corticosteroid therapy re-
sulted in complete regression of symptoms and the 
patient was discharged from the hospital for home 
care. He was recommended to take oral corticosteroids 
daily, according to the following tapering-off  scheme: 
methylprednisolone 80 mg for 10 days, then 64 mg for 
14 days, followed by 32 mg for 14 days, then 16 mg for 
14 days, and fi nally methylprednisolone 8 mg. At neu-
rological follow-up examination performed 3 months 
later, the patient was still complaining of blurred vision 
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on the right eye, subjectively. Neurological and oph-
thalmological examination was performed and was 
regarded normal. Follow-up contrast enhanced MRI 
of the brain was performed and showed signifi cant re-
gression of the post-contrast signal intensity in the 
right cavernous sinus, previously extending basally to-
wards the trigeminal cave and anteriorly towards the 
apex of the right orbit, with right-sided temporal-bas-
al dural sheath imbibition and imbibitions along the 
clivus (Fig. 5). Th e patient was suggested to continue 
with oral corticosteroid therapy and recommended 4 
mg methylprednisolone daily, and has not experienced 
relapse ever since.
Discussion
Th is case report presents the patient diagnosed 
with THS after extensive neurodiagnostic and MRI 
evaluation, which was the most important diagnostic 
tool in deriving the diagnosis of THS. Follow-up con-
trast enhanced MRI of the brain, performed 3 months 
after corticosteroid therapy administration, revealed 
complete regression of the pathologic substrate, thus 
confi rming the effi  cacy of corticosteroid treatment. 
Th e study based on data from THS studies published 
from 1999 to 2007 examined credibility of the ICHD 
criteria for THS diagnosis. Study results confi rmed 
that defi nitive diagnosis of THS should be based on 
brain MRI, which was positive in 92.1% of THS pa-
tients because regression of symptoms was confi rmed 
in only 2% of patients within 72 hours after corticoste-
roid therapy application. Data analysis of the possible 
infl ammatory process localization included not only 
the cavernous sinus, but also the orbit (THS plus syn-
drome or pseudotumor)3. Furthermore, MRI analysis 
showed residual signs of infl ammation after the symp-
toms had subsided, thus suggesting that infl ammation 
might be present up to several months after regression 
of symptoms. Depending on the infl ammatory infi l-
trate location, patients might present with various 
nonspecifi c symptoms that include nerve compression 
in cavernous sinus, partial or complete ophthalmople-
gia indicating superior orbital fi ssure involvement, or 
loss of vision indicating optic nerve involvement; iso-
lated trochlear nerve paresis has also been described4. 
Alternative diagnosis also included an extracranial du-
ral metastatic neoplasm lesion, imitating meningioma 
that required surgical removal procedure. Th e major 
limitation of MRI fi ndings in THS is their lack of 
specifi city. A study that examined 11 patients has re-
ported pathologic MRI fi ndings in the cavernous sinus 
in nine patients. In six of these nine patients, the af-
fected cavernous sinus was enlarged, and in fi ve of nine 
patients it had a convex lateral wall. Extension into the 
orbital apex was seen in eight patients. Yet, the signal 
characteristics (hypointense relative to fat and isoin-
tense with muscle on T1 weighted images; isointense 
with fat on T2 weighted scans) were also consistent 
with meningioma, lymphoma, and sarcoidosis. Exten-
sive diagnostic evaluation is warranted to exclude al-
ternative causes of painful ophthalmoplegia and to 
confi rm THS diagnosis5. Th erefore, diagnostic pro-
cessing usually includes complete laboratory work-up, 
thyroid hormone analysis, brain MRI and MRA, lum-
bar puncture and CSF analysis, vasculitis assessment, 
an ophthalmologist and otolaryngologist examination, 
x-ray of the heart and lungs, abdomen ultrasound, and 
fi nally biopsy of the lesion previously verifi ed by brain 
MRI. Th e above is important for the successful treat-
ment of THS and other diff erential diseases. In the 
literature, one can fi nd diff erent doses of corticoste-
roids applied for THS treatment because there are no 
specifi c guidelines for the THS therapeutic approach. 
During hospitalization, our patient had partially re-
covered spontaneously, but after systemic corticoste-
roid treatment, regression of symptoms was complete. 
We treated our patient with the intravenously applied 
corticosteroid therapy with 1 gram of methylpredniso-
lone daily, applied for 3 consecutive days. Following 
systemic therapy, the patient was tapered down to low-
er doses of corticosteroids, applied orally. Some au-
thors used lower doses of oral corticosteroids (60 mg 
or 125 mg), and had positive therapeutic response6. 
When corticosteroids are contraindicated or serious 
side eff ects are present, corticosteroid treatment should 
be discontinued. Patients on long-term corticosteroid 
use and persistent or recurrent symptoms could be 
treated with azathioprine, methotrexate or radiation 
therapy7-9. Literature data show that symptom regres-
sion and normalization of MRI fi ndings occur faster 
in patients treated with high-dose corticosteroids in 
comparison to low-dose corticosteroids, although the 
diff erence was not statistically signifi cant. Recurrence 
of symptoms was recorded in 44.2% of patients treated 
with low-dose corticosteroids, as opposed to 10% of 
patients treated with high-dose corticosteroids, sug-
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gesting the importance of patient follow-up10. Patient 
observation during therapy application, continuous 
follow-up and cranial MRI follow-up with the focus 
on the cavernous sinus and orbital apex is recommend-
ed in the evaluation of THS symptom regression and 
therapeutic effi  cacy11–15.
Conclusion
Th e diagnosis of THS is often made after alterna-
tive disease processes have been excluded. Extensive 
diagnostic evaluation is warranted to exclude the pos-
sible causes of painful ophthalmoplegia. Diff erential 
diagnosis of THS includes parasellar syndrome causes 
(trauma), neoplasms (primary intracranial tumor, local 
or distant metastases), vascular causes (aneurysm, ca-
rotid dissection, carotid cavernous fi stula), infl amma-
tion (orbital pseudotumor, giant cell arteritis, sarcoid-
osis), infectious etiology (fungi, mycobacteria, etc.)12 or 
other (micro vascular infarcts, diabetes mellitus, recur-
rent painful ophthalmoplegic neuropathy). Additional 
causes of painful ophthalmoplegia include orbital dis-
ease, posterior fossa aneurysm and ophthalmoplegic 
migraine. Evidently, various disorders and disease pro-
cesses are included in the diff erential diagnosis of 
THS, thus patients suspected of having THS require 
careful evaluation, appropriate treatment, and follow-
up observation of therapy applied.
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Sažetak
TOLOSA-HUNTOV SINDROM – PRIKAZ SLUČAJA
S. Zečević Penić, M. Lisak, T. Gregurić, H. Hećimović i V. Bašić Kes
Ovaj prikaz slučaja opisuje bolesnika kojem je dijagnoza Tolosa-Huntova sindroma (THS) postavljena nakon opsežne 
neuro-dijagnostičke obrade. Dijagnostička obrada je obuhvatila temeljit fi zički i neurološki pregled, kompletnu procjenu 
laboratorijskih vrijednosti u serumu, neuroendokrinu i imunohistokemijsku analizu, analizu cerebrospinalne tekućine, neu-
rofi ziološke testove, oftalmološki pregled i slikovne pretrage mozga. Najvažnija dijagnostička metoda u izvođenju dijagnoze 
THS-a bio je osnovni i kontrolni slikovni prikaz mozga pomoću magnetske rezonancije (MR) pojačane kontrastom. Osnov-
ni MR prikaz mozga je otkrio nespecifi čnu upalnu granulomatoznu leziju u desnom kavernoznom sinusu s imbibicijom 
prema bazalno i prema Meckelovoj šupljini te anteriorno prema vrhu desne orbite. Sustavna intravenska terapija visokim 
dozama kortikosteroida primijenjena je kroz 3 uzastopna dana te je nastavljena primjena oralnih kortikosteroida prema 
shemi postupnog snižavanja doze. Nakon terapije nastupila je regresija simptoma, a kontrolni MR mozga pojačan kontra-
stom pokazao je značajnu regresiju upalne lezije u području desnog kavernoznog sinusa, čime je potvrđena učinkovitost lije-
čenja. Ovaj prikaz slučaja pokazuje da je opsežna dijagnostička obrada nužna prije postavljanja dijagnoze THS-a i primjene 
terapije kako bi se isključili alternativni poremećaji. Bolesnici za koje se sumnja da imaju THS zahtijevaju pažljivu neuro-
dijagnostičku procjenu, odgovarajući terapijski pristup i praćenje ishoda liječenja.
Ključne riječi: Tolosa-Huntov sindrom – dijagnostika; Tolosa-Huntov sindrom – farmakoterapija; Magnetska rezonancija, 
snimanje; Kortikosteroidi; Prikazi slučaja
